Scarica l'app Stockscreener
1.43
0.69%
-0.01
Pre-mercato:
1.44
0.01
+0.70%
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
Allogene Therapeutics’ ALLO-329 Snags FDA Fast Track Designations for 3 Rheumatology Indications - CGTLive®
Allogene's ALLO-329 Granted Three FDA Fast Track Designations - Nasdaq
Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases - MarketScreener
Allogene received FDA Fast-track statuses for its dual CAR-Therapy - Seeking Alpha
Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329 - MarketScreener
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - The Manila Times
FDA grants fast track status to Allogene’s autoimmune therapy - Investing.com
Groundbreaking Triple FDA Fast Track: Allogene's New CAR T Targets Multiple Autoimmune Diseases - Stock Titan
Allogene stock plunges to 52-week low of $1.32 amid steep annual decline - Investing.com
Allogene stock plunges to 52-week low of $1.32 amid steep annual decline By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India
Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com Australia
Allogene Therapeutics CEO sells $91,469 in stock - Investing.com India
Allogene Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Renal Cancer Clinical Pipeline | 75+ Companies, Including - openPR.com
7th Annual Allogeneic Cell Therapies Summit - pharmaphorum
Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com
Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India
Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech
Allogene upgraded at Citizens after Q4 update - MSN
Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... By GuruFocus - Investing.com Canada
Citizens Capital Markets Upgrades Allogene Therapeutics (ALLO) - Nasdaq
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... - Yahoo
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlight - GuruFocus.com
Citi maintains Buy on Allogene stock with $8 price target By Investing.com - Investing.com Australia
Allogene stock upgraded at Citizens post Q4 (ALLO:NASDAQ) - Seeking Alpha
Citi maintains Buy on Allogene stock with $8 price target - Investing.com India
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil - Yahoo Finance
Allogene Therapeutics: Q4 Earnings Snapshot - The Wilton Bulletin
Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations - Investing.com India
Allogene Therapeutics Inc Q4 Loss Per Share $0.28 -March 13, 2025 at 05:32 pm EDT - Marketscreener.com
Allogene Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Estimates; Revenue Falls Short - GuruFocus.com
Allogene Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALLOGENE THERAPEUTICS Earnings Results: $ALLO Reports Quarterly Earnings - Nasdaq
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - The Manila Times
Allogene Therapeutics: Q4 Earnings Snapshot -March 13, 2025 at 05:05 pm EDT - Marketscreener.com
Allogene Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - Yahoo Finance
CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire
Foresight Diagnostics expands Allogene partnership - BizWest
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):